Superseded public profile

Not FDA-approved↗Unapproved and safety records↗↗

Superseded · version 2: CJC-1295↗

Related names recorded in this version: CJC-1295 DAC↗

FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form. 3

What this version reported

FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗

Sources for this version

  1. 1
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  3. 3
    FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026